Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources
- PMID: 7527901
- DOI: 10.1016/0161-5890(94)90051-5
Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources
Abstract
CD30L, the ligand for the activation antigen CD30, is a member of the tumor necrosis factor family of cytokines. Binding of CD30L to CD30, which is a member of the nerve growth factor/tumor necrosis factor receptor family, induces proliferation in peripheral blood lymphocytes and Hodgkin's derived cell lines with a T-cell phenotype such as HDLM-2 and L540, while cell lines derived from anaplastic large cell lymphomas, such as Karpas 299, undergo cell death. In order to investigate whether mutations of the CD30 antigen are responsible for these opposite effects, we cloned the open reading frame of CD30 cDNAs from the cell lines L540 and Karpas 299 and from peripheral blood lymphocytes by reverse transcriptase polymerase chain reaction. Sequencing of independent plasmid clones revealed that these cells have a silent transition (A-->G) at position 771 of the open reading frame compared to the published sequence derived from the HTLV-1+ cell line HUT-102. As published data have shown that crosslinking of CD30 induces an elevation of cytosolic free calcium ([Ca2+]i) in TCR positive Jurkat cells, we have analysed the effect of crosslinking of CD30 on L540 and Karpas 299 cells. No elevations of [Ca2+]i have been observed in these cell lines after crosslinking of CD30 with HRS-4. We conclude (i) that the different functional effects of CD30 in PBL, L540 and Karpas 299 are not due to differences in the primary structure of the receptor; and (ii) that the different responses observed upon engagement with CD30L for the cell lines L540 and Karpas 299 do not correlate with differences in mobilization of [Ca2+]i after crosslinking of CD30.
Similar articles
-
Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.Leukemia. 1994 Dec;8(12):2083-94. Leukemia. 1994. PMID: 7528856
-
CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.Leuk Lymphoma. 1996 Feb;20(5-6):397-409. doi: 10.3109/10428199609052421. Leuk Lymphoma. 1996. PMID: 8833395 Review.
-
CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.Cancer Res. 1995 Sep 15;55(18):4157-61. Cancer Res. 1995. PMID: 7545087
-
Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.Lab Invest. 2000 Jul;80(7):1111-9. doi: 10.1038/labinvest.3780117. Lab Invest. 2000. PMID: 10908157
-
CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation.Leuk Lymphoma. 1999 Sep;35(1-2):21-35. doi: 10.3109/10428199909145702. Leuk Lymphoma. 1999. PMID: 10512160 Review.
Cited by
-
CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.Am J Pathol. 2008 Feb;172(2):510-20. doi: 10.2353/ajpath.2008.070858. Epub 2008 Jan 10. Am J Pathol. 2008. PMID: 18187570 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous